Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations
Jenny O’Nions(University College London Hospitals NHS Foundation Trust), Sylvain Garciaz(Centre National de la Recherche Scientifique), Valentina Mancini(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Andrew H. Wei(The Royal Melbourne Hospital), Kathryn Packman(Johnson & Johnson (United States)), Olga Salamero(Vall d'Hebron Institut de Recerca), Amir T. Fathi(University of Southern California), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Jordi Esteve(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Marie Luise Hütter‐Krönke(University Hospital Ulm), Brett Hiebert(Johnson & Johnson (United States)), Marina Konopleva(Albert Einstein College of Medicine), Pierre Bories, Juan Manuel Alonso‐Domínguez(Hospital Universitario Fundación Jiménez Díaz), Jan Krönke(Universitätsmedizin Greifswald), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), James Dugan(Novant Health), Prathap Nagaraja Shastri(Springhouse), Emma Searle(University of Manchester), Ana Alfonso Piérola(Istituti di Ricovero e Cura a Carattere Scientifico), Lucille Ferrante(Johnson & Johnson (United States)), Natalia Tovar(Hospital Clínic de Barcelona), Christina Loefgren(Janssen (United States)), Ibrahim Aldoss(City of Hope), Laura Barreyro(Albert Einstein College of Medicine), Christina Guttke(Johnson & Johnson (United States)), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Oliver Lomas(Johnson & Johnson (United States)), Matteo Della Porta(University of Milan), Sara Garrido Paniagua(Vall d'Hebron Institut de Recerca), Pasquale L. Fedele(Monash Health), Nicolas Vallet(Université de Tours), Ana Garrido(Hospital de Sant Pau), Madlen Jentzsch, Paresh Vyas(University of Oxford), Uwe Platzbecker(National Center for Tumor Diseases), Emmanuel Gyan(Inserm), Hartmut Döhner(University Hospital Ulm), Tim Sauer(Heidelberg University), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Lachlin Vaughan(Westmead Hospital), Daniel Morillo(Sheba Medical Center), Christoph Röllig, Amber D'Souza(Johnson & Johnson (United States)), Alicia J. Allred(Queen's University Belfast), Naa Sackey(Johnson & Johnson (United States)), Nikki Daskalakis(Johnson & Johnson (United States))
Cited by 4
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k